Overview

Biomarker Guided Treatment in DLBCL

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Cyclophosphamide
Decitabine
Doxorubicin
Lenalidomide
Prednisone
Rituximab
Vincristine